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Abstract
Background: Genomes of men and women differ in only a limited number of genes located on the sex
chromosomes, whereas the transcriptome is far more sex-specific. Identification of sex-biased gene expression will
contribute to understanding the molecular basis of sex-differences in complex traits and common diseases.
Results: Sex differences in the human peripheral blood transcriptome were characterized using microarrays in 5,241
subjects, accounting for menopause status and hormonal contraceptive use. Sex-specific expression was observed
for 582 autosomal genes, of which 57.7% was upregulated in women (female-biased genes). Female-biased genes
were enriched for several immune system GO categories, genes linked to rheumatoid arthritis (16%) and genes
regulated by estrogen (18%). Male-biased genes were enriched for genes linked to renal cancer (9%). Sex-differences in
gene expression were smaller in postmenopausal women, larger in women using hormonal contraceptives and not
caused by sex-specific eQTLs, confirming the role of estrogen in regulating sex-biased genes.
Conclusions: This study indicates that sex-bias in gene expression is extensive and may underlie sex-differences in the
prevalence of common diseases.
Background
Sexual dimorphism extends into marked cellular, meta-
bolic, physiological and anatomical differences and leads
to sex differences in disease prevalence, expression and se-
verity of, for example, cardiovascular [1], and autoimmune
[2] diseases, personality [3] and psychiatric disorders [4].
Sex inequalities are an increasingly recognized challenge
in both basic research and clinical medicine [5], and
understanding the molecular mechanisms behind sex dif-
ferences may lead to new insights into sex-specific patho-
physiology and treatment opportunities [6].
Sex differences at the DNA sequence level are restricted
to the sex chromosomes. On the X-chromosome, most
genes are equally expressed across sex due to X-inactiva-
tion in women [7]. The few unshared genes located on the
Y chromosome are exclusively expressed in the testes, or
are housekeeping genes with X-chromosome homologues
that escape X-inactivation [8]. However, genome regula-
tion seems highly sex-specific at secondary epigenetic
levels such as DNA methylation [9], DNase hypersensi-
tivity [10], chromatin structure [11] and gene expres-
sion [12,13]. Thus, a characterization of sex differences
in genome regulation by gene expression will contribute
to the understanding of the molecular basis of sexual
dimorphism.
Animal studies have shown that sex-biased gene expres-
sion is highly tissue dependent [14,15] and the evolution
rates of sex-biased genes are higher than average [12,16].
Two recent studies in mice reported sex differences in
gene expression networks of correlated transcripts [17,18].
Surprisingly few studies aimed at identifying and inves-
tigating sex-biased genes in humans, and only in small
sample sizes (N < 250 [19-22]). Nonetheless, consistent
evidence was obtained for sex-specific gene expression.
Sex-differences in gene expression will depend on the
hormonal status of the group considered. For instance,
during menopause, much of the female-specific hormone
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production ceases, with downstream effects on gene ex-
pression in adipose tissue [23], monocytes [24], and bone
[25]. In women using hormonal contraceptives, containing
the hormones estrogen and progesterone, additional dif-
ferences in gene expression may be evident as well.
For many genes, expression levels are influenced by
DNA polymorphisms (eQTLs). Although the sexes do not
differ at the autosomal DNA sequence level, sex differ-
ences in gene expression may be caused by sex-specific
eQTLs [26] (i.e. some SNPs may influence gene expression
in one sex, but not in the other).
Here we used microarrays to identify genome-wide sex-
biased gene expression in the human peripheral blood
transcriptome in a large sample (N = 5241 subjects) from
the Netherlands. The sample size was sufficiently large to
account for menopause status and hormonal contraceptive
use. The identified sex-biased genes were characterized in
terms of enrichment for functional gene ontology (GO)
and disease categories, distribution across the autosomes
and sex chromosomes, tissue specificity, evolution rates,
participation in major gene expression networks and the
extent to which sex differences in gene expression were
caused by sex-specific eQTLs.
Results
Sample description
The sample consisted of 5,241 individuals from the
Netherlands Study of Depression and Anxiety (NESDA)
and Netherlands Twin Register (NTR) cohorts (Table 1;
[27]). Of the women, 22% were postmenopausal and
31% used hormonal contraceptives. For all participants,
genome-wide gene expression in peripheral blood was
assessed using microarrays with 47,122 probe sets target-
ing 19,250 genes. For each probe set, mixed models
including demographic, and several technical covariates
were used to test for sex effects (see Methods).
Sex effects on gene expression
Sex effects on gene expression were determined by com-
paring men (N = 1,814) and premenopausal women who
did not use hormonal contraceptives (N = 1,594). When
considering 45,418 autosomal transcripts targeting
18,495 genes, 993 transcripts from 582 genes (3.1% of all
autosomal genes measured) were significantly influenced
by sex (p < 1.2e-6, Bonferroni corrected at p < 0.05, FDR
< 6e-5). The percentage of sex-biased genes increased
when only genes with a mean expression above a certain
threshold were considered. For example, a mean expres-
sion threshold of 5 (log2(intensity)) resulted in 5.5% sex-
biased genes, and using a threshold of 9 resulted in
13.7% sex-biased genes (Figure 1A). However, there were
several transcripts with low mean expression level but
with a high fold change between the sexes (Figure 1B).
In order to provide a comprehensive overview, we in-
cluded all transcripts in the following analyses.
Female-biased versus male-biased genes
From the sex-biased transcripts on the autosomes, 572
(57.7%) were upregulated in females (female-biased
genes, Figure 1C), and 421 in males (male-biased genes,
Figure 1B). For each sex-biased transcript the loge fold
change was computed (Figure 1D). For female-biased
transcripts the fold change was computed as the mean
expression in females/mean expression in males, for
male-biased genes we used -mean expression in males/
mean expression in females. Most absolute loge fold
changes were smaller than 0.08 (99%), for 22 transcripts the
absolute loge fold change was larger than 0.08 (6 female-
biased, targeting the genes ADM, CREB5, CNTNAP3,
C9orf84, SORCS2 and GPR109A and 14 in men (KANK2,
CTSG, MPO, BPI, GPER, DEFA4, EPB49, C19orf62, ERG,
LCN2, CEACAM8, LTF, FECH and LTBP1), see Additional
file 1 for sex-biased genes and corresponding fold changes
and p-values).
On the X chromosome, 1643 transcripts from 739 genes
were measured. Out of these, 127 transcripts from 51
genes were sex-biased; 103 (from 38 genes) were female-
biased, and 24 (from 13 genes) male-biased. Seventeen
of the corresponding loge fold changes were larger than
0.08 (targeting the genes EIF1AX, PRKX, KDM5C, ZFX,
KDM6A, XIST, VSIG4, TSIX and SCARNA9L). Only the
loge fold changes of the genes XIST and TSIX were larger
than 0.5. Of the 63 transcripts targeting 26 genes on the
Y chromosome, 48 transcripts from 16 genes had expres-
sion levels in men that were higher than the noise mea-
sured in women; 12 transcripts had a loge fold change
larger than 0.5, targeting the genes EIF1AY, DDX3Y
KDM5D, CYorf15B, CYorf15A and UTY.
Genomic location of sex-biased genes
For each chromosome we tested whether the genes on
that chromosome enriched the sex-, male- or female-
biased genes. At the autosomes, the percentage of sex-
biased genes differed only slightly between chromosomes,
Table 1 Demographic summary of sample
Female Male
Total # subjects (after QC) 3427 1814
group (NTR/NESDA) 2079/1348 1147/667
age (mean/sd) 38.5/12.7 38.9/13.7
bmi (mean/sd) 25.6/4.1 24.5/4.6
smoking status (percentage of smokers) 27.00% 32.00%
red blood cell count 8.3/0.6 9.4/0.6
Menopause status females (pre/post) 2687/740
Contraceptive pill use (yes/no) 1093/2334
The sample consisted of 5241 subjects (after QC) from the Dutch NESDA
and NTR cohorts.
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ranging from 1.6% on chromosome 20 to 4.2% on
chromosome 14 (Figure 1E); none of the autosomes
enriched the sex-biased genes (p > 0.05, Fisher's exact test).
The distribution of the male- and female-biased genes
over the autosomes was more variable, ranging from 0.4%
at chromosome 20 to 2.3% at chromosome 18 (female-
biased genes), and from 0.7% at chromosome 4 to 2.4% at
chromosome 22 (male-biased gene), however none of the
autosomes enriched female or male-biased genes. As ex-
pected, female-biased genes were enriched for genes at the
X-chromosome (5.1%), and male-biased genes for genes at
the Y chromosome (61%).
Figure 1 Characterization of female- and male-biased genes. For each of the 47,122 transcripts the sex effect was determined using a mixed
model, resulting in 3.1% sex-biased genes. A) Transcripts were selected based on a threshold for mean expression, the percentage of sex-biased
genes increases with the threshold that is used: in genes that are highly expressed there are more (up to 13%) sex-biased genes than in genes
that have low expression. Nonetheless, also large male/female fold changes were observed in genes with low (B) and moderate (C) expression.
D) For each transcript fold changes were computed; on the autosomes 57.7% of the sex-biased genes was female-biased, and absolute loge fold
changes ranged from 0 to 0.2. E) For each chromosome, the number of male- and female-biased genes was computed, only the Y and X
chromosomes were enriched for male- and female-biased genes, respectively.
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Gene ontology (GO) analysis of sex-biased genes
Female-biased genes were enriched for 52 biological
process GO categories (BPGO) (p < 0.01, Bonferroni cor-
rection, see Additional file 2 for significant GO categor-
ies and female-biased genes therein), with as top hit
immune system process (31.6% of female-biased genes
are in this category, p < 1e-25). Significant subcategories
included response to cytokine stimulus (11.3%, p < 1e-10),
response to type 1 interferon (3.6%, p < 1e-7) and lympho-
cyte differentiation (5.6%, p < 1e-5). Male-biased genes
were not enriched for any BPGO category. The female-
biased genes were enriched for 7 cellular component
GO (CCGO) categories (top hits are cell surface (8.3%,
p < 1e-6) and integral to membrane (31.3%, p < 1e-5)).
Male-biased genes were enriched for 11 CCGO categories,
with as top hit cytoplasm (73.4%, p < 1e-10) and significant
subcategory lysome (6.4%, p < 1e-4). In Additional file 3
the hierarchical network structure of the significant GO
categories is visualized.
Ingenuity pathway analysis (IPA) of sex-biased genes
From the IPA biological functions, autoimmune disease
(22%, FDR < 1e-11 (Fisher's exact test)) and rheumatoid
arthritis (16%, FDR < 1e-11 (Fisher's exact test)) enriched
the female-biased genes most significantly, among 21
other autoimmune diseases (Additional file 4). The up-
stream regulator lipopolysaccharide (LPS, 26%, p < 1e-27
(uncorrected p-value Fisher's exact test)) was most
strongly associated with the female-biased genes, among
many other regulators (Additional file 5) such as estradiol
(18%, p < 1e-9 (uncorrected p-value Fisher's exact test)).
Male-biased genes were most significantly enriched for
genes linked to renal cancer (9%, FDR < 1e-5 (Fisher's
exact test), Additional file 6). There were only few male-
biased genes influenced by the same upstream regula-
tors (Additional file 5, top hits were GATA (3%, p < 1e-5
(Fisher's exact test)) and HIPK2 (2%, p < 1e-4 (Fisher's
exact test))).
eQTL analysis of sex-biased gene expression
eQTL analysis was performed using two sample subsets
of 1523 men and 1373 premenopausal women who did
not take hormonal contraceptives, for which genome-
wide SNP and gene expression data were available (see
Methods). For each of the 993 autosomal sex-biased
transcripts, eQTLs were computed for men and women
separately. At a FDR of 0.01 there were 7978 cis eQTLs
(p < 6e-05) and 514 trans eQTLs (p < 2e-09)) for men,
and 6731 cis eQTLs (p < 5.2e-05) and 197 trans eQTLs
(p < 1.8e-09)) for women. For the pooled eQTLs (9659 cis,
545 trans eQTLs) genotype-sex interactions were assessed
using a mixed model that included data from men and
women. At a FDR of 0.05 no significant genotype-sex
interactions were observed.
Sex-biased genes highly enrich modules of correlated
transcripts
Weighted Gene Co-Expression Network Analysis (WGCNA)
[28] was used to identify modules of correlated tran-
scripts, for men and women separately. Both analyses
resulted in 9 modules with >70% transcript overlap be-
tween the male and the corresponding female module
for 8 of the 9 modules (Additional file 7). One module
had only ~40% overlap. Thus, gene expression correl-
ation structure is similar between men and women, and
here we focus on properties of the intersection of the
overlapping modules. Interestingly, 7 of these inter-
sected modules were highly enriched with female-
biased or male-biased genes. There were three modules
with more than 30% male-biased genes, and two mod-
ules with more than 30% female-biased genes. The
modules were highly enriched for several GO terms
(Additional file 7). We calculated the pairwise transcript
correlations within each intersected module or men and
women separately. For two modules containing male-
biased genes the correlations were significantly stronger
in males than in females (76% of the correlations were
stronger in module #6, and 92% in module #9, Figure 2A
& B respectively). Thus, these modules contained around
30% of male-biased genes, but also the majority (> 75%) of
the interactions in the module were stronger in males
compared to females.
Evolution rates of sex-biased genes
To test whether sex-biased genes have evolved faster
than non sex-biased genes, we tested for enrichment in
two sets of genes that were previously identified as rapidly
evolving: 244 genes from the Human PAML Browser [29]
and 40 genes from a study comparing human and chim-
panzee genomes [30]. Sex-biased, male-biased and female-
biased genes were not enriched for any of the two gene
sets (Fisher's exact test, p > 0.05). Next, we tested whether
dN, dS and dN/dS (the evolution rates) as provided by
[31] were different in sex-biased, male-biased and female-
biased genes compared to non sex-biased genes, but found
no significant differences (all p > 0.05, Wilcoxon rank test).
Tissue specificity of sex-biased genes
We downloaded analysis results of two human studies
that identified sex-biased genes in muscle [22] and in
liver [21]. In muscle, 63 sex-biased genes were identified
on the autosomes which were enriched with the sex-
biased genes we identified (8 genes identified in both
tissues, p < 0.01 (Fisher's exact test), Additional file 8).
On the X chromosome 5 genes were identified as sex-
biased in muscle, of which 4 were also identified in
blood (p < 0.001 (Fisher's exact test), Additional file 8).
In liver, 862 sex-biased genes were identified on the au-
tosomes which were enriched with the sex-biased genes
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we identified (36 genes identified in both tissues, p < 0.05
(Fisher's exact test), Additional file 8). On the X chromo-
some 50 genes were identified as sex-biased in liver, of
which 18 were also identified in blood (p < 1e-9 (Fisher's
exact test), Additional file 8).
Sex-biased genes in postmenopausal and hormonal
contraceptive using women
To examine whether sex differences in gene expression
depend on hormonal status, sex effects were computed by
comparing men (N = 1,814) with postmenopausal women
(N = 740) and women using hormonal contraceptives (HC
women, N = 1,093). On the autosomes, there were 697
transcripts differentially expressed between postmeno-
pausal women and men. From these 697 transcripts
(369 female-biased and 328 male-biased) 236 over-
lapped with the 993 sex-biased transcripts identified
in non-hormonal contraceptives using premenopausal
(NHC) women. When comparing the HC women with
men, a much larger number of 2,125 differentially
expressed transcripts were identified (1,157 female-biased,
968 in male-biased). From these transcripts, 755 were
overlapping with the 993 sex-biased transcripts identified
in NHC women. For the 933 transcripts identified in
NHC women, loge fold changes were computed for the
difference between each of the three groups of women
(NHC, HC, postmenopausal) compared to men. When
comparing these fold changes between postmenopausal
and NHC women, it became clear that most of the fold
changes have the same sign (85% in total, 99% of the ne-
gative fold changes) but that the fold changes in NHC
women are larger than those in postmenopausal women
for 80% of the transcripts (Figure 3A). Also the fold
changes of NHC women and HC women often have the
same sign (96%), and the fold changes of HC women
were often larger than those observed in NHC women
(66% of all fold changes, 88% of the negative fold
changes, Figure 3B). This shows that many gene expres-
sion differences between women and men become smaller
when women reach menopause, and are larger when
women use hormonal contraceptives, which reinforces the
role of estrogen in regulating sex-biased genes.
Age specific sex effects on gene expression
Age has a strong influence on gene expression [32]. To
examine whether sex effects on gene expression are age-
range specific, we separately analyzed the data for three
age groups (men versus premenopausal women who did
not use hormonal contraceptives, age ranges 17-30 (N =
1047), 31-40 (N = 1191) and 41-88 (N = 1170)). In these
3 age groups we identified 49, 103 and 34 autosomal
sex-biased genes respectively (p < 1.2e-6, Additional
file 9), which overlapped for >98% with the sex-biased
genes identified in the total sample (with same direc-
tion of effect). The three sets of sex-biased genes iden-
tified in these age groups overlapped to a lesser extent
with each other (>38%, Additional file 9). However, the
fold changes between men and women of the sex-biased
genes identified in the total sample were highly con-
cordant between age ranges (Additional file 10), sug-
gesting that the identified sex effects occur at all ages,
but that some effects may be stronger at a certain age or
may not have been identified due to reduced power in
the smaller groups of selected ages.
Figure 2 Between transcript correlations are higher in males than in females for 2 modules. WGCNA (Weighted Gene Co-Expression Network
Analysis) resulted in 9 modules with correlated transcripts, two of which were highly enriched for female-biased genes, and 3 for male-biased genes. From
the latter three, two modules contained genes from which the pair-wise correlations were stronger in males compared to females. A) Module
#6 contained 45 genes, 76% of the correlations computed in males (y axis) were larger than those computed in females (x axis). B) Module #9
contained 35 genes, 92% of the correlations computed in males (y axis) were larger than those computed in females (x axis).
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Discussion
At the DNA autosomal sequence level sexes do not dif-
fer, as established by a well-powered meta-analysis [33],
suggesting an important role for higher molecular levels,
such as the transcriptome, in the manifestation of sexual
dimorphisms. Indeed, animal studies have shown that
the transcriptome is highly differential between sexes
[14,15,34,35]. In humans, gene expression differences
have been reported in liver [21], lymphoblastoid cell
lines [19,20], and muscle [22], but only in studies with
relatively small sample sizes (N < 250). Here we analyzed
the sex differences in the peripheral blood transcriptome
by assessing 47,122 probe sets targeting 19,250 genes
genome wide in a well-characterized large Dutch cohort
(N = 5,241) taking into account the impact of hormonal
contraceptive use and menopausal status in women.
Number of female- and male-biased genes
On the autosomes, we identified 582 genes (3.1% of all
genes measured) that were differentially expressed be-
tween men and premenopausal women not using hor-
monal contraceptives. Of these genes, 57.7% were
female-biased. The autosomes had rather similar propor-
tions of sex-biased genes indicating the sex-biased genes
can be found equally frequent across the entire genome,
as opposed to what was found in liver [21] where several
chromosomes enrich sex-biased genes. It is important to
note that the filter criteria used for selecting probe sets
highly influences the number of sex-biased genes; the
percentage of sex-biased genes increased with the thresh-
old for mean expression level from 3.1% up to 13.7%.
Importantly, we have shown that hormonal contraceptives
and menopause status, which were not taken into account
in previous studies in humans, highly influence the num-
ber and effect sizes of sex differences in gene expression.
Although it has been indicated that the percentage of sex-
biased genes in non-human vertebrates is highly tissue
dependent (e.g. ranging from 13.6% in the brain to 72% in
the liver [14,15]), our described range of 3.1-13.7% for sex-
biased genes is comparable to that found in human liver
(3.7%, [21]). Peripheral blood consists of a mixture of
blood cell types (the main types are lymphocytes, neutro-
philes and monocytes), hence the sex differences we iden-
tified must either be present in all subcell types or, when
present in only one cell type, strong enough to be ob-
served in the accumulative measurement. By stratifying
the sample into three age groups we showed that the size
of the sex effects may be age dependent for some genes,
but the direction of the effects are highly concordant
between age groups.
We found a significant but small overlap of sex-biased
autosomal genes identified in peripheral blood with
those previously identified in muscle or liver, further con-
firming substantial tissue specificity of sex-biased genes.
Across tissue circulating exosomes contain RNA and
could contribute to the overlapping expression profiles be-
tween muscle, liver and blood [36]. Sex-biased X chromo-
some genes showed must larger overlap between tissues,
indicating that escape from X-inactivation is highly similar
between tissues. Previous studies have reported that sex-
biased genes may evolve more rapidly than average in ver-
tebrates [12], human brain [37] and liver [21]. However,
sex-biased genes in the peripheral blood transcriptome
identified in our study did not include enrichment of fast
evolving genes. In women, most genes on one X chromo-
some are not expressed due to X chromosome inactivation
Figure 3 Sex-differences in gene expression are increased by the use of hormonal contraceptives, and decreased during menopause.
Women were divided in three groups: postmenopausal, hormonal contraceptive using (HC), and non hormonal contraceptive using (NHC) women. For
the 993 sex-biased transcripts identified in the comparison between males and NHC women, fold changes were computed for the difference between
the three groups of women and the men. Positive fold changes are from female-biased genes, negative fold changes correspond to male-biased genes.
A) Fold changes are for 80% larger in NHC women as compared to postmenopausal women. B) Fold changes in HC women are for 66% larger than
those observed in NHC women, and the negative fold changes (male-biased genes) were for 88% larger in HC women.
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[38]. Some genes escape X-inactivation and are expressed
from both X chromosomes [7]. We showed that in periph-
eral blood the X chromosome is enriched for female-
biased genes; 5.1% of the genes measured on the X
chromosome are female-biased. This percentage, however,
is only slightly higher than the average percentage identi-
fied at the autosomes (3.1%), which shows a major role of
autosomal genes in sex-specific gene expression.
The role of estradiol in gene expression sex differences
Estrogen is the primary female sex hormone and estro-
genic activity is present at about two fold increased con-
centration in women as compared to men. Estradiol, the
predominant estrogen in terms of absolute serum levels,
activates estrogen receptors that bind to DNA sequences
to activate or suppress gene expression, and many efforts
have been made to find its target genes (up to 5000) in
MCF-7 cancer cell line [39-41] because of its role in
breast cancer [42]. Here we show that in peripheral
blood 18% of the identified sex-biased genes are known
to be regulated by estradiol, and several additional find-
ings suggest that the sex difference in estrogen levels
underlie multiple sex differences in gene expression.
First, from the 20 genes with high male/female fold
changes, 7 are involved in common diseases and influ-
enced by estrogen; GPER (g protein-coupled estrogen
receptor-1, related to cancer [43]), ADM (coding for the
peptide adrenomedulin, the main vasodilatory peptide
involved in cardiovascular disease [44-46], LTF (lactofer-
rin, essential for the innate immune system and involved
in cancer [47,48]), LCN2 (lipocalin-2, innate immune
system and cancer related [49]), MPO (myeloperoxi-
dase), a biomarker for cardiovascular disease risk [50],
ERG (Ets Related Gene, proposed as a mediator of estro-
gen effect on prostate cancer [51], LTBP1 (latent-trans-
forming growth factor beta-binding protein 1, linked to
coronary heart disease [52]. This suggests that these
genes mediate the effect of estrogen and thereby may
contribute to the sex differences in the related diseases.
Second, we showed that the sex differences in gene
expression depend largely on the hormonal status of the
subgroup of women considered. In postmenopausal
women, in which estradiol levels are similar to those in
men, we identified fewer sex-biased genes with smaller
effect sizes as compared to premenopausal women. In
hormonal contraceptive using women, with increased
estradiol levels, we identified more sex-biased genes and
larger effect sizes as compared to women not using hor-
monal contraceptives. Interestingly, the change in effect
size was present for more than 65% of the female-biased
genes, and for more than 85% of the male-biased genes.
This gives an indication of the amount of sex-biased
genes affected by estradiol, which is much higher than
currently known from literature (IPA, 15% of sex-biased
genes are known to be regulated by estradiol). In liver,
sex differences in gene expression are mainly caused by
sex-specific growth hormone secretion [21,53]. Growth
hormones are regulated by estrogen [54,55], hence the
effect of estrogen on sex-specific gene expression in
peripheral blood may also be mediated by growth hor-
mone secretion.
Immune system processes predominant in female-biased
genes
The immune system function is known to be different
between sexes; women produce more vigorous immune
reactions and are more prone to autoimmune diseases
[56]. Here we identified a large number of genes that
potentially contribute to the immune system sex dif-
ferences; 31.6% of female-biased genes are in the GO
category immune system process. From the 95 female-
biased genes linked to the immune system, 45 are regu-
lated by estradiol, which confirms the role of estrogen in
the sex-specific immune system functioning [57]. Most
interestingly, Ingenuity Pathway Analysis revealed that
female-biased genes are highly enriched for genes involved
in the toll-like receptor (TLR4 and TLR3 pathways,
known as LPS and poly I:C response patterns) driven in-
nate immune defense, suggesting some intrinsic innate
immune activity sex differences. Increased female expres-
sion of immunoglobulin is reflective of concomitant more
active humoral immune activity. These functions are com-
patible with an activated leukocyte, cytokine production
and type 1 interferon activity observed in the GO enrich-
ment analysis and might explain why women are more re-
sistant to certain infections, and suffer a high incidence of
autoimmune diseases compared to men [2]. For example,
rheumatoid arthritis occurs almost twice as often in
women as in men [58]. Female-biased genes were enriched
for genes linked to rheumatoid arthritis, including the
gene IL6R, which is a well-known target in rheumatoid
arthritis treatment [59]. The identified female-biased genes
provide a framework for future research to unravel the
mechanism of sex-biased immune regulation and auto-
immune diseases.
Annotation of male-biased genes
Surprisingly, male-biased genes were not enriched for GO
categories, and thus serve a wide variety of biological func-
tions. In IPA, however, male-biased genes were most
significantly enriched for genes linked to renal cancer, in-
cluding the well established renal cancer gene CSF1R [60].
It is notable that a recent meta-analysis on sex differences
in renal cell cancer presentation and survival showed a ra-
tio of 1.65 of renal cell carcinoma for males compared to
females [61]. The cellular component GO categories indi-
cate the part of a cell at which a gene product is located.
Topographical categorization revealed that male-biased
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gene products occur more often intracellularly, in particu-
lar at the cytoplasm, whereas female-biased genes occur
more often integral to the membrane.
Sex-specific eQTLs do not underly sex-biased gene
expression
A previous study (in a smaller sample than the current
one) showed that a substantial amount of eQTLs is sex-
specific, but not for eQTLs from genes with sex-biased
expression [26]. Here we confirm this finding by show-
ing that for the sex-biased genes there were no signifi-
cant eQTL-sex interactions. This shows the importance
of other factors, such as estradiol and other hormones,
in causing gene expression sex differences.
Sex-biased genes in modules of correlated transcripts
WGCNA analyses resulted in highly similar modules of
correlated transcripts for men and women, similar to
findings in mice [18]. The 9 modules were highly
enriched for male or female-biased genes, indicating that
sex-biased genes play an important role in the major
gene expression networks. Module #2 and #3 contained
each more than 30% female-biased genes and were
enriched for the GO category immune system response,
which shows that immune system genes operate in corre-
lated groups that are partially sex-biased. Module #9 con-
tained 31.4% male biased genes, enriched the GO category
immune response (37%) and contained 92% stronger pair-
wise correlations in men than in women. This module
contained the interleukin receptor IL2B gene, and IPA
analysis showed that 11 of the 35 genes in this module are
known to be regulated by the cytokine IL2, and 16 of them
are related to cancer (Additional file 11) including the
female-biased genes PRF1 and GZMH essential for natural
killer (NK)-cell cytotoxicity [62,63]. Module #6 contained
37.8% male-biased genes, was enriched for the GO term
coagulation (50%) and 76% of the pairwise correlations in
this module are higher in men than in women. IPA ana-
lysis shows that from this module 16 genes are regulated
by TGFB1 (Additional file 11), and 17 genes are related to
heart or vascular disease, including the male-biased genes
PTGS1 (coding for COX-1, which is inhibited by aspirin
[64] that has a protective effect on cardiac events [65]),
ITGA2B, ITGB3, F13A and GP1BA which are candidate
stroke risk genes [66]. This suggests that the modules #9
and #6 may play a role in the sex differences in cancer and
cardiovascular disease, respectively.
Conclusions
We showed that sex-biased genes occur in large num-
bers throughout the human peripheral blood transcrip-
tome, suggesting an important role of sex-specific gene
expression in sexual dimorphisms. Estrogen appears to
be a key regulator of sex-biased genes, also shown by
the effect of menopause and hormonal contraceptives
on gene expression sex differences. Sex-biased genes are
highly enriched with genes linked to common diseases
and may contribute to sex-differences in these diseases.
Understanding the molecular mechanisms behind sex
inequalities can lead to new insights into sex-specific
pathophysiology and treatment opportunities.
Methods
Subjects
The two parent projects that supplied data for this study
are large-scale longitudinal studies: the Netherlands
Study of Depression and Anxiety (NESDA) [67] and the
Netherlands Twin Registry [68]. NESDA and NTR stud-
ies were approved by the Central Ethics Committee on
Research Involving Human Subjects of the VU Univer-
sity Medical Center, Amsterdam (IRB number IRB-2991
under Federalwide Assurance 3703; IRB/institute codes,
NESDA 03-183; NTR 03-180), and all subjects provided
written informed consent. The sample consisted of 5391
subjects (before QC), 3327 participants from NTR (2
MZ triplets, 708 MZ twin pairs, 658 DZ twin pairs, 338
siblings from these twins and 251 unrelated individuals)
and 2064 unrelated participants from NESDA. The age
of the participants ranged from 17 to 88 years (mean 38,
SD 13) and 65% of the sample was female. As part of the
NESDA and NTR biobank protocols, data on meno-
pause status and medication use, including hormonal
contraceptives were collected in all participants.
Blood sampling, RNA and DNA extraction
The NTR and NESDA blood sampling and RNA extrac-
tion procedures have been described in detail previously
[69,70]. In short; for NTR, venous blood samples were
drawn between 0700-1100 after an overnight fast and
usually in the subjects’ homes. Within 20 minutes of
sampling, heparinized whole blood was transferred into
PAXgene Blood RNA tubes (Qiagen) and stored at -20°C.
The PAXgene tubes were shipped to the Rutgers Univer-
sity Cell and DNA Repository (RUCDR), USA. Average
time between blood sampling and RNA extraction was
211 weeks (included in mixed model for gene expression).
Upon registration of samples, RNA was extracted using
Qiagen Universal liquid handling system (PAXgene extrac-
tion kits as per the manufacturer's protocol).
From the NESDA subjects, serial venous whole blood
samples were obtained (8–10 AM, after overnight fast-
ing) in one 7-mL heparin-coated tube (Greiner Bio-One,
Monroe, North Carolina). Between 10 and 60 min after
blood draw, 2.5 mL of blood was transferred into a PAX-
gene tube (Qiagen, Valencia, California). This tube was
kept at room temperature for a minimum of 2 hours
and then stored at −20°C. Average time between blood
sampling and RNA extraction was 113 weeks (included
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in mixed model for gene expression). Total RNA was ex-
tracted at the VU University Medical Center (Amsterdam)
according to the manufacturer’s protocol (Qiagen) as de-
scribed previously [70].
For both NESDA and NTR samples high molecular
weight genomic DNA was isolated from frozen blood in
EDTA tubes using Puregene DNA isolation kits (Qiagen).
Gene expression measurements
Gene expression assays were conducted at the Rutgers
University Cell and DNA Repository (RUCDR, http://
www.rucdr.org). RNA quality and quantity was assessed
by Caliper AMS90 with HT DNA5K/RNA LabChips.
RNA samples that showed abnormal ribosomal subunits
in the electropherograms were removed. NTR and NESDA
samples were randomly assigned to plates with seven plates
containing subjects from both studies to better inform
array QC and study comparability. For cDNA synthesis,
50 ng of RNA was reverse-transcribed and amplified in
a plate format on a Biomek FX liquid handling robot
(Beckman Coulter) using Ovation Pico WTA reagents per
the manufacturer’s protocol (NuGEN). Products purified
from single primer isothermal amplification (SPIA) were
then fragmented and labeled with biotin using Encore Bio-
tin Module (NuGEN). Prior to hybridization, the labeled
cDNA was analyzed using electrophoresis to verify the ap-
propriate size distribution (Caliper AMS90 with a HT
DNA 5 K/RNA LabChip). Samples were hybridized to
Affymetrix U219 array plates (GeneTitan) to enable high-
throughput gene expression profiling of 96 samples at a
time. The U219 array contains 530,467 probes for 49,293
transcripts. All probes are 25 bases in length and designed
to be “perfect match” complements to a designated tran-
script. Array hybridization, washing, staining, and scan-
ning were carried out in an Affymetrix GeneTitan System
per the manufacturer’s protocol.
Genome-wide SNP measurements and QC
Genotyping was conducted using Affymetrix Genome-
Wide Human SNP Array 6.0 containing 931,946 SNPs,
per the manufacturer’s protocol. The resulting data were
required to pass standard Affymetrix QC metrics (contrast
QC > 0.4) before further analysis. SNP QC included
removal of SNPs for non-unique mapping of probe
sequences to NCBI Build 37/UCSC hg19, low minor
allele frequency (< 0.005), substantial deviation from
HapMap3 CEU founder allele frequencies, deviation
from Hardy-Weinberg equilibrium (pHWE < 1×10
-8), and
high missingness (> 0.05). After genotyping QC, 666 K
autosomal SNPs were available. Subjects were elimi-
nated from analysis for high missingness (> 0.05), outly-
ing genome-wide homozygosity or ancestry, discrepant
genetic and phenotypic sex, or twin relatedness not
consistent with monozygosity or dizygosity.
Gene expression QC
Gene expression data were required to pass standard
Affymetrix QC metrics (Affymetrix expression console)
before further analysis. Probes were removed when their
location was uncertain or if their location intersected a
polymorphic SNP (dropped if the probe oligonucleotide se-
quence did not map uniquely to hg19 or if the probe con-
tained a polymorphic SNP based on HapMap3 and 1000
Genomes project data). Expression values were obtained
using RMA normalization implemented in Affymetrix
Power Tools (APT, v 1.12.0). First, 70 samples with array
results inconsistent with the phenotypic database were
removed (inconsistent sex based on chr X and chr Y probe
sets). Second, we used the pairwise correlation matrix
of expression profiles across all arrays for additional QC.
These quantities were expressed in terms of median abso-
lute deviations to provide a sense of scale. We used:
Di¼ ri‐rj jmedian rk‐rj jð Þk¼1:::N
With ri the average of correlations for sample i, and r
the average of all correlations. Larger values of D corre-
sponded to poor quality; 80 samples with D > 5 were re-
moved, decreasing the final number of subjects to 5,241.
Mixed models for gene expression
Linear mixed models allow for the correction for the
presence of twin families in a sample [71]. For each of
the 47,122 probe sets a mixed model was fit with gene
expression as dependent variable. Independent model
covariates were selected based on significance of the
variable in the fitted mixed models. Several covariates
that did not come out significantly were not included in
the final model (alcohol use, education level, time be-
tween RNA amplification and RNA fragmentation, time
between RNA fragmentation and RNA hybridization).
Inclusion of depression status and psychotropic medica-
tion use as covariates in the mixed model did not affect
the principle findings. Fixed effect covariates included in
the final model were sex, age, body mass index (BMI,
weight/height 2 in kg/m), smoking status (yes/no current
smoking), D (see above), hemoglobin (mmol/L), group
(NTR or NESDA), time of blood sampling, month of
blood sampling, time between blood sampling and RNA
extraction, and the time between RNA extraction and
RNA amplification. Random effects were plate, well,
family ID and zygosity (one factor for each monozygotic
twin pair, for each other individual different factors
[71]). In Additional file 12, for each of the variables the
amount of probe sets for which the variable was signifi-
cant is denoted. Mixed models and resulting p-values
were computed using the R function lmer from the
package lme4.
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eQTL analysis
eQTL analysis was first performed in a screening step by
MatrixeQTL [72]. Prior to eQTL analysis for each gene
expression probeset the data was transformed into a nor-
mal distribution using an inverse quantile normal trans-
formation. Genotypes were coded as 0, 1 or 2 and for each
SNP-transcript pair a linear regression model was fitted
including the covariates sex, age, body mass index, smok-
ing status, D (see above), hemoglobin (mmol/L), group
(NTR or NESDA), time of blood sampling, month of
blood sampling, time between blood sampling and RNA
extraction, time between RNA extraction and RNA ampli-
fication, plate and well plus three principle components
(PCs) from the genotype data [73] and 5 PCs from the
transformed expression data. Cis-eQTLs are transcript-
associated SNPs with distance < 1 Mb of transcript site.
The trans-eQTLs are the complementary set of SNPs.
In the screening step, males and woman were screened
using MatrixeQTL as if the individuals were all un
related. Benjamini-Hochberg q-value estimation was
performed separately for cis- and trans-eQTLs. For each
of the 993 autosomal sex-biased transcripts eQTLs were
selected for men and women separately, and then
pooled. For these eQTLs genotype-sex interactions were
assessed using the full mixed model that included both
men and women, with as independent variables geno-
type, sex, their interaction and the other covariate also
used in the mixed model for gene expression (see above).
GO category enrichment
To test whether Gene Ontology [74] categories enriched
sex-biased genes we used hypergeometric tests imple-
mented in BINGO software [75]. The reference gene set
consisted of all genes measured by the U219 microarrays.
WGCNA
The correlation structure of gene expression was exam-
ined using unsigned co-expression networks constructed
using the WGCNA package in R [28]. Of all 47,122 probes
a single probe of highest mean expression per gene was
selected to be included in the network analysis using the
CollapseRows function in WGCNA, resulting in the inclu-
sion of 19,249 genes in the network. The choice of the
probe of highest mean expression per gene has been
shown to yield robust analysis across data sets [76]. The
network construction for each entire data set was per-
formed in a single block of maximum size 20,000 genes
using the blockwiseModules function in WGCNA [28].
Using this block size in WGCNA ensured the theoretical
advantage that the genes did not have to be pre-clustered
by WGCNA. The network adjacency matrix is the gene
pair-wise correlation matrix raised to the power of 6,
chosen based on the scale-free topology criteria [77]. Ra-
ther than just using adjacency weights between genes, the
topological overlap measure (TOM) is computed from the
adjacency matrix. For each pair of genes, TOM is the adja-
cency weights of all the paths between the genes of length
at most two (i.e. the genes are directly connected or have
one gene between them) scaled by the minimum connect-
ivity of the either gene. The topological overlap dissimilar-
ity, defined as 1-TOM, is used for the average linkage
hierarchical clustering algorithm. The resultant clustering
tree is used to define the modules from its branches using
the hybrid dynamic tree cutting algorithm [28]. The mini-
mum module size was set to 30 and the cut-off for mer-
ging modules was set to 0.25. Each module is then
characterized by its eigengene, the first principal compo-
nent of the module expression data, which accounts for
the greatest variation of the expression levels in the mod-
ule. Genes were removed from modules if the correlations
between their expression values and the module eigen-
genes were too low (less than 0.3). Modules were merged
if the correlation between their eigengenes was high.
Availability of supporting data
Gene expression data used for this study will be available at
dbGaP, accession number phs000486.v1.p1 (http://www.
ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=p
hs000486.v1.p1).
Additional files
Additional file 1: Sex-biased genes and corresponding p-values and
loge fold change.
Additional file 2: Significant GO categories for female-biased genes.
Additional file 3: Hierarchical structure of Gene Ontology
categories enriching male or female-biased genes. GO enrichment
analysis for female (A, B) and male-biased genes (C) in the main categories
biological process (A, C) and cellular component (B). GO categories are
represented as circles, size of circle shows total amount of genes in this
category, color of circle codes for p-value for enrichment (the color white
means not significant). An arrow pointing from category A to category B
means that B is a subcategory of A. GO categories containing few genes
with no further subcategories often occur at the outside of the network,
and provide the most specific classification, such as categories response to
type 1 interferon, lymphocyte differentiation, anti-apoptosis and lysome.
Additional file 4: Autoimmune diseases enriching female-biased
genes.
Additional file 5: Upstream regulators associated with sex-biased
genes.
Additional file 6: Male biased genes associated with renal cancer.
Additional file 7: Characterization of modules.
Additional file 8: Sex-biased genes identified in multiple tissues.
Additional file 9: Sex-biased genes in three age ranges.
Additional file 10: Fold changes of sex-biased genes in three age
groups. Subject were divided in three age groups: 18-30, 31-40, and 41-88.
For the 993 sex-biased transcripts identified in the full sample, fold changes
between men and women were computed within the three groups and
plotted against each other. The figures show that the fold changes are
highly concordant between age ranges.
Additional file 11: Characterization of genes in Modules #6 and #9.
Additional file 12: Covariates selected for mixed model.
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